MA29259B1 - 2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2 - Google Patents
2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2Info
- Publication number
- MA29259B1 MA29259B1 MA30150A MA30150A MA29259B1 MA 29259 B1 MA29259 B1 MA 29259B1 MA 30150 A MA30150 A MA 30150A MA 30150 A MA30150 A MA 30150A MA 29259 B1 MA29259 B1 MA 29259B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutically acceptable
- xvi
- urticaria
- solvate
- inflammation
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 208000024780 Urticaria Diseases 0.000 abstract 2
- 201000008937 atopic dermatitis Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 206010053582 Bronchopneumopathy Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000004262 Food Hypersensitivity Diseases 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 abstract 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000008736 Systemic mastocytosis Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 235000020932 food allergy Nutrition 0.000 abstract 1
- 150000004678 hydrides Chemical class 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010036784 proctocolitis Diseases 0.000 abstract 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 abstract 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 238000006748 scratching Methods 0.000 abstract 1
- 230000002393 scratching effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (XVI) DANS LAQUELLE R, R2, R3, R4, R5, R6, R7 ET N SONT TELS QUE DÉFINIS ICI OU UN SEL, HYDRATE OU SOLVATE DE CELUI-CI ACCEPTABLES DU POINT DE VUE PHARMACEUTIQUE, UN PROMÉDICAMENT ACCEPTABLE DU POINT DE VUE PHARMACEUTIQUE DE CELUI-CI OU UN SEL, HYDRATE OU SOLVATE ACCEPTABLES DU POINT DE VUE PHARMACEUTIQUE DU PROMÉDICAMENT, UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UNE QUANTITÉ EFFICACE DU POINT DE VUE PHARMACEUTIQUE D'UN OU PLUSIEURS COMPOSÉS SELON LA FORMULE (XVI) EN MÉLANGE AVEC UN VÉHICULE ACCEPTABLE DU POINT DE VUE PHARMACEUTIQUE, UN PROCÉDÉ CONSISTANT À TRAITER UN PATIENT SOUFFRANT D'UN TROUBLE MÉDIÉ PAR LA PGD2 DONT, MAIS IL N'EST PAS LIMITÉ À CEUX-CI, UNE MALADIE ALLERGIQUE (TELLE QUE LA RHINITE ALLERGIQUE, LA CONJONCTIVITE ALLERGIQUE, LA DERMATITE ATOPIQUE, L'ASTHME BRONCHIQUE ET UNE ALLERGIE ALIMENTAIRE), UNE MASTOCYTOSE SYSTÉMIQUE, DES TROUBLES S'ACCOMPAGNANT D'UNE ACTIVATION SYSTÉMIQUE DES MASTOCYTES, LE CHOC ANAPHYLACTIQUE, LA BRONCHOCONSTRICTION, LA BRONCHITE, L'URTICAIRE, L'ECZÉMA, DES MALADIES S'ACCOMPAGNANT DE DÉMANGEAISONS (TELLES QUE LA DERMATITE ATOPIQUE ET L'URTICAIRE), DES MALADIES (TELLES QUE LA CATARACTE, LE DÉCOLLEMENT DE LA RÉTINE, UNE INFLAMMATION, UNE INFECTION ET DES TROUBLES DU SOMMEIL) QUI SONT GÉNÉRÉES DE FAÇON SECONDAIRE EN CONSÉQUENCE D'UN COMPORTEMENT S'ACCOMPAGNANT DE DÉMANGEAISONS (TEL QU'UN GRATTEMENT ET UN BATTAGE), UNE INFLAMMATION, DES BRONCHO-PNEUMOPATHIES CHRONIQUES OBSTRUCTIVES, UNE PLAIE DE REPERFUSION ISCHÉMIQUE, UN ACCIDENT CÉRÉBROVASCULAIRE, LA POLYARTHRITE RHUMATOÏDE CHRONIQUE, LA PLEURÉSIE, LA RECTO-COLITE HÉMORRAGIQUE ET SIMILAIRES EN ADMINISTRANT AU DIT PATIENT UNE QUANTITÉ EFFICACE DU POINT DE VUE PHARMACEUTIQUE D'UN COMPOSÉ SELON LA FORMULE (XVI).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64730705P | 2005-01-26 | 2005-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29259B1 true MA29259B1 (fr) | 2008-02-01 |
Family
ID=36282872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30150A MA29259B1 (fr) | 2005-01-26 | 2007-08-17 | 2-phénylindoles en tant qu'antagonistes du récepteur de la prostaglandine d2 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20070265278A1 (fr) |
| EP (1) | EP1844011A1 (fr) |
| JP (1) | JP2008528606A (fr) |
| KR (1) | KR20070110277A (fr) |
| CN (1) | CN101146770A (fr) |
| AR (1) | AR054726A1 (fr) |
| AU (1) | AU2006209213A1 (fr) |
| BR (1) | BRPI0607079A2 (fr) |
| CA (1) | CA2595728A1 (fr) |
| CR (1) | CR9214A (fr) |
| DO (1) | DOP2006000016A (fr) |
| GT (1) | GT200600030A (fr) |
| IL (1) | IL184816A0 (fr) |
| MA (1) | MA29259B1 (fr) |
| MX (1) | MX2007008277A (fr) |
| NO (1) | NO20074336L (fr) |
| PA (1) | PA8661201A1 (fr) |
| PE (1) | PE20060878A1 (fr) |
| RU (1) | RU2007132166A (fr) |
| SG (1) | SG158918A1 (fr) |
| TN (1) | TNSN07251A1 (fr) |
| TW (1) | TW200639151A (fr) |
| UY (1) | UY29346A1 (fr) |
| WO (1) | WO2006081343A1 (fr) |
| ZA (1) | ZA200705449B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007276885A1 (en) * | 2006-07-25 | 2008-01-31 | Sanofi-Aventis | 2-phenyl-indoles as prostaglandin D2 receptor antagonists |
| MY147588A (en) | 2006-08-07 | 2012-12-31 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
| WO2008061006A1 (fr) * | 2006-11-10 | 2008-05-22 | Wyeth | Indan-2-yl arylsulfonamides substitués et leurs procédés d'utilisation |
| US8362056B2 (en) * | 2007-11-05 | 2013-01-29 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives |
| CA2790139C (fr) | 2010-03-22 | 2018-03-13 | Actelion Pharmaceuticals Ltd | Derives de 3-(heteroarylamino)-1,2,3,4-tetrahydro-9h-carbazole et leur utilisation comme modulateurs du recepteur de la prostaglandine d2 |
| US8722719B2 (en) * | 2010-10-06 | 2014-05-13 | Kureha Corporation | Amine compound and use for same |
| JP5964945B2 (ja) | 2011-04-14 | 2016-08-03 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用 |
| EP2548863A1 (fr) * | 2011-07-18 | 2013-01-23 | Almirall, S.A. | Nouveaux antagonistes de CRTH2 |
| EP2762141A4 (fr) * | 2011-09-29 | 2015-03-25 | Shionogi & Co | Produit pharmaceutique thérapeutique contre la rhinite allergique comportant un antagoniste de pgd2 et un antagoniste d'histamine |
| CN104011021B (zh) | 2011-12-21 | 2016-08-24 | 埃科特莱茵药品有限公司 | 杂环衍生物及其作为前列腺素d2受体调节剂的用途 |
| US9169270B2 (en) | 2012-07-05 | 2015-10-27 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| WO2014066568A1 (fr) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Biomarqueur non invasif permettant d'identifier des sujets risquant un accouchement avant terme |
| JP6168520B2 (ja) * | 2013-09-17 | 2017-07-26 | 国立大学法人 千葉大学 | インドール化合物、ｄｐプロスタノイド受容体アンタゴニスト、それを用いた薬剤、及びｄｐプロスタノイド受容体アンタゴニストの使用。 |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| CA2939892C (fr) | 2014-03-17 | 2020-03-31 | Idorsia Pharmaceuticals Ltd | Derives d'acide aza-indol-acetique et leur utilisation comme modulateurs des recepteurs de la prostaglandine d2 |
| CN106103437A (zh) | 2014-03-18 | 2016-11-09 | 埃科特莱茵药品有限公司 | 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途 |
| CN108026093B (zh) | 2015-09-15 | 2021-11-16 | 爱杜西亚药品有限公司 | 结晶形式 |
| US20200264188A1 (en) | 2017-09-13 | 2020-08-20 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| EP4070113A4 (fr) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié |
| CN113173877B (zh) * | 2020-10-30 | 2023-10-27 | 江西师范大学 | 吲哚乙酰基亚氨基砜系列化合物及其制备方法 |
| CN115925606B (zh) * | 2023-01-05 | 2023-10-13 | 宁夏医科大学 | 一种5-（3-（磺酰胺基）苯基）-1h-吡咯-2-羧酸衍生物及其制备方法和应用 |
| EP4691466A1 (fr) | 2023-07-25 | 2026-02-11 | The Eye Hospital of Wenzhou Medical University | Utilisation d'un inhibiteur de ptgds dans la préparation d'un médicament pour le traitement de la cataracte |
| CN117599052A (zh) * | 2023-07-25 | 2024-02-27 | 温州医科大学附属眼视光医院 | Ptgds的抑制剂在制备治疗白内障药物上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5496844A (en) * | 1992-05-08 | 1996-03-05 | Otsuka Pharmaceutical Factory, Inc. | Indole derivatives |
| FR2751966B1 (fr) * | 1996-08-01 | 1998-10-30 | Union Pharma Scient Appl | Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique |
| US6500853B1 (en) * | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| DE10204462A1 (de) * | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
| JP2004024655A (ja) * | 2002-06-27 | 2004-01-29 | Aruze Corp | 遊技機 |
| JPWO2004078719A1 (ja) * | 2003-03-06 | 2006-06-08 | 小野薬品工業株式会社 | インドール誘導体化合物およびその化合物を有効成分とする薬剤 |
| SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1771169A1 (fr) * | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Procedes pour le traitement de l'hepatite c |
-
2006
- 2006-01-20 DO DO2006000016A patent/DOP2006000016A/es unknown
- 2006-01-24 PE PE2006000105A patent/PE20060878A1/es not_active Application Discontinuation
- 2006-01-25 SG SG201000540-3A patent/SG158918A1/en unknown
- 2006-01-25 KR KR1020077017292A patent/KR20070110277A/ko not_active Withdrawn
- 2006-01-25 EP EP06719551A patent/EP1844011A1/fr not_active Withdrawn
- 2006-01-25 GT GT200600030A patent/GT200600030A/es unknown
- 2006-01-25 AR ARP060100278A patent/AR054726A1/es not_active Application Discontinuation
- 2006-01-25 WO PCT/US2006/002736 patent/WO2006081343A1/fr not_active Ceased
- 2006-01-25 RU RU2007132166/04A patent/RU2007132166A/ru not_active Application Discontinuation
- 2006-01-25 CA CA002595728A patent/CA2595728A1/fr not_active Abandoned
- 2006-01-25 JP JP2007553221A patent/JP2008528606A/ja active Pending
- 2006-01-25 BR BRPI0607079-5A patent/BRPI0607079A2/pt not_active IP Right Cessation
- 2006-01-25 AU AU2006209213A patent/AU2006209213A1/en not_active Abandoned
- 2006-01-25 CN CNA2006800097886A patent/CN101146770A/zh active Pending
- 2006-01-25 MX MX2007008277A patent/MX2007008277A/es not_active Application Discontinuation
- 2006-01-26 TW TW095102967A patent/TW200639151A/zh unknown
- 2006-01-26 PA PA20068661201A patent/PA8661201A1/es unknown
- 2006-01-26 UY UY29346A patent/UY29346A1/es unknown
-
2007
- 2007-06-28 CR CR9214A patent/CR9214A/es not_active Application Discontinuation
- 2007-07-03 TN TNP2007000251A patent/TNSN07251A1/en unknown
- 2007-07-04 ZA ZA200705449A patent/ZA200705449B/xx unknown
- 2007-07-24 IL IL184816A patent/IL184816A0/en unknown
- 2007-07-25 US US11/782,890 patent/US20070265278A1/en not_active Abandoned
- 2007-08-17 MA MA30150A patent/MA29259B1/fr unknown
- 2007-08-24 NO NO20074336A patent/NO20074336L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1844011A1 (fr) | 2007-10-17 |
| UY29346A1 (es) | 2006-08-31 |
| IL184816A0 (en) | 2007-12-03 |
| TW200639151A (en) | 2006-11-16 |
| ZA200705449B (en) | 2009-01-28 |
| RU2007132166A (ru) | 2009-03-10 |
| AR054726A1 (es) | 2007-07-11 |
| KR20070110277A (ko) | 2007-11-16 |
| TNSN07251A1 (en) | 2008-12-31 |
| WO2006081343A1 (fr) | 2006-08-03 |
| JP2008528606A (ja) | 2008-07-31 |
| US20070265278A1 (en) | 2007-11-15 |
| AU2006209213A1 (en) | 2006-08-03 |
| PA8661201A1 (es) | 2006-09-08 |
| PE20060878A1 (es) | 2006-10-18 |
| MX2007008277A (es) | 2007-09-07 |
| GT200600030A (es) | 2006-09-27 |
| NO20074336L (no) | 2007-10-23 |
| CR9214A (es) | 2007-11-23 |
| CN101146770A (zh) | 2008-03-19 |
| BRPI0607079A2 (pt) | 2009-08-04 |
| SG158918A1 (en) | 2010-02-26 |
| DOP2006000016A (es) | 2006-07-31 |
| CA2595728A1 (fr) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30409B1 (fr) | Amino-pyrimidine 2,6-substituee-4-mono-substituee en tant qu'antagoniste du recepteur de la prostaglandine d2. | |
| MA30643B1 (fr) | 2-phenylindoles en tant qu'antagonistes du recepteur de la prostaglandine d2. | |
| MA30005B1 (fr) | Sel dihydrogenophosphate d'un antagoniste du recepteur de la prostaglandine d2 | |
| JP3935201B2 (ja) | 神経弛緩薬ａｆｓとしてのｎ−置換されたアザビシクロアルカン誘導体 | |
| US9580400B2 (en) | Cannabinergic nitrate esters and related analogs | |
| Sharma et al. | 5-Hydroxytryptophan: a precursor of serotonin influences regional blood-brain barrier breakdown, cerebral blood flow, brain edema formation, and neuropathology | |
| MA27575A1 (fr) | Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoires | |
| MA29692B1 (fr) | Derives de la xanthine en tant qu'agonistes selectifs du hm74a | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
| MA27926A1 (fr) | Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1 | |
| BRPI0516482A (pt) | 2, 6-substituìda-4-monossubstituìda-amino-pirimidina como antagonistas receptor de prostaglandina d2 | |
| MA30289B1 (fr) | Dérivés d'amines | |
| BG65030B1 (bg) | Нестероидни противовъзпалителни средства | |
| NO20074336L (no) | 2-fenylindoler som prostaglandin D2 reseptorantagonister | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| US20130045975A1 (en) | Bicyclic heteroaryl inhibitors of pde4 | |
| MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
| JP2007530601A5 (fr) | ||
| CN1116928A (zh) | 眼用组合物 | |
| JPH06501030A (ja) | 神経系および精神系不調を処置するためのインドール誘導体、医薬組成物および方法 | |
| EA005824B1 (ru) | СОЕДИНЕНИЯ, ЭФФЕКТИВНЫЕ В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ PDE4 | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| EP0534343B1 (fr) | Pyridinylamino-1H-indoles, 1H-indazoles, 2H-indazoles, benzo(b)thiophènes et 1,2-benzinothiazoles substituées, procédé pour leur préparation et leur utilisation comme médicaments | |
| MA29336B1 (fr) | Derives d'aryl-1,4-pyrazine substitues |